Ipca Laboratories' Q2 FY 2025-26 Quarterly Results

Result Summary

• Ipca Laboratories Ltd reported a 10.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 8.5%.
• Its expenses for the quarter were up by 6.1% QoQ and 4.8% YoY.
• The net profit increased 20.5% QoQ and increased 14.2% YoY.
• The earnings per share (EPS) of Ipca Laboratories Ltd stood at 11.14 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Ipca Laboratories Ltd is a leading pharmaceutical company based in India, recognized for its significant contribution to the healthcare industry. The company is primarily engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Ipca Laboratories serves a wide range of therapeutic segments including cardiovascular, anti-diabetic, anti-malarial, and pain management, among others. Known for its robust research and development capabilities, the company has established a strong presence in both the domestic and international markets. As of the latest updates available up to October 2023, there are no specific recent major developments provided in the data; however, the company's consistent focus remains on expanding its product portfolio and enhancing its market reach.

Revenue

In the second quarter of the fiscal year 2026 (Q2FY26), Ipca Laboratories Ltd reported a total income of ₹2,584.36 crores. This represents a quarter-over-quarter (QoQ) increase of 10.4% compared to the previous quarter (Q1FY26), where the total income was ₹2,341.51 crores. Additionally, the year-over-year (YoY) growth from the same quarter in the previous fiscal year (Q2FY25), where the total income was ₹2,381.16 crores, stood at 8.5%. The increase in total income over both periods highlights the company's ability to enhance its revenue streams through effective strategies in market penetration and product offerings.

Profitability

For Q2FY26, Ipca Laboratories Ltd recorded a profit before tax of ₹391.58 crores, reflecting an 18.5% growth on a QoQ basis from ₹330.51 crores in Q1FY26, and a 13.6% increase YoY from ₹344.83 crores in Q2FY25. The profit after tax for the quarter was ₹280.53 crores, which shows a 20.5% QoQ rise from ₹232.89 crores in the previous quarter and a 14.2% YoY growth from ₹245.75 crores in the same quarter last year. These figures indicate that the company's profitability has improved, driven by effective cost management and revenue growth. The tax expense for the quarter was ₹108.08 crores, marking a 12.5% increase QoQ and an 8.7% rise YoY.

Operating Metrics

The total expenses for Ipca Laboratories Ltd in Q2FY26 amounted to ₹2,134.52 crores, which demonstrates a 6.1% increase QoQ from ₹2,011.00 crores in Q1FY26, and a 4.8% increase YoY from ₹2,036.33 crores in Q2FY25. The company's earnings per share (EPS) for the quarter were ₹11.14, representing a 21.2% QoQ growth from ₹9.19 in the previous quarter and a 23.1% YoY increase from ₹9.05 in the same quarter of the previous year. These metrics reflect the company's operational efficiency and its ability to generate higher earnings for its shareholders. The growth in EPS suggests an improvement in shareholder value, potentially driven by the company's strategic initiatives and business performance.